



Tuesday, 27th September 2022

**Newly appointed members to the Board of Directors
and Management Team in preparation for clinical
trial execution.**

InhaleRx Ltd “**IRX**” appoints new board members to lead the
company

InhaleRx Ltd has appointed:

- Mr. Darryl Davies as Chief Executive Officer
- Dr Rob Jenny as Chief Scientific Officer
- Dr John Crock as Non-Executive Director

InhaleRx Limited (ASX:IRX) ('InhaleRx' or 'Company') is pleased to announce the appointment of Mr. Darryl Davies as Chief Executive Officer effective immediately. Mr Davies will step down as Executive Director of the Company from today's date.

Darryl Davies joined the InhaleRx Limited board on 20th July 2021 and brings with him over 16 years' experience in psychology, harm minimisation and healthcare commercialisation. Mr. Davies has scaled wellness device company and co-founded private medicinal cannabis service provider, Cannvalate Pty Ltd, best known for award-winning patient access programs, end-to-end distribution solutions and their specialty cannabinoid and psychedelic Clinical Research Organisation, iGENū CRO.

Mr. Davies also launched Australia's first university-partnered educational programmes for the cannabis industry and has coordinated doctor education initiatives across Australia. Darryl has global industry relationships and serves as an advisor and Director to both domestic and international public and private biotech companies.

Mr. Davies said, “I look forward to the next exciting chapter in InhaleRx's development and I'll be working closely with the highly credentialed board and management team in leading the execution of the Company's strategic plans across the lifecycle of the two clinical trial

programmes. In addition, I'll be focusing on new opportunities to develop novel inhalation drug / device therapies to address unmet clinical needs".

Mr. Davies' CEO appointment is to be on a part-time basis pursuant to an Executive Services Agreement. His remuneration will be \$135,000 per annum (plus superannuation entitlements) to be paid monthly. Mr. Davies' employment with the Company will also be subject to a 6 month notice period upon termination by either party.

Dr Rob Jenny, PhD, is appointed Chief Scientific Officer, a biochemist by training with experience in R&D, commercialisation, pharma manufacturing and as an ASX company director.

Dr Jenny has a passion for bringing life science, biotech, and healthcare innovations to market. With the bench-to-bedside pathway in mind he started his career genetically engineering and turning stem cells into respiratory cells for regenerative medicine.

Since completing a PhD and an MBA Dr Jenny has been involved in numerous commercialisation efforts involving universities, start-ups and pharmaceutical and personal care manufacturers. Dr Jenny possesses both the scientific and commercial acumen to support the development and expansion of the company assets.

Rob will be deployed across the two programmes to oversee the scientific, regulatory and tech transfer process to ensure the trials are ready to commence in accordance with the anticipated timeline.

Dr John Crock, MBBS FRACS MD DA MAHSS is appointed a Non-Executive Director and is a highly experienced plastic surgeon with over 40 years of clinical experience. He has received multiple awards over the course of his career.

Dr Crock is the founder of Aussie Health Abroad, an international aid organisation that focuses on training surgeons in developing nations, but also interfaces with many other disciplines of medicine in the global community - particularly in the USA and Europe.

Dr Crock has practiced as a clinical supervisor/ senior lecturer at Monash Health and as well as having an academic appointment at Monash University, also teaches at Melbourne University and is on the faculty for the Graduate Diploma of Surgical Anatomy.

Dr Crock has completed an MD thesis which has been published in international journals and has been presented at major scientific forums in the USA, UK and Australia.

Dr Crock has been an active member of many medical advisory boards including Knox Private Hospital. He has also been actively involved in the Royal Flying Doctor Service and has coordinated international retrieval exercises on numerous occasions.

Dr Crock will be advising on the clinical aspects of both programmes and he plans to offer his wealth of clinical experience in the use of inhaled medicines combined with his access to his extensive esteemed medical network.

Approved by the Board of Directors.

For Further information:

Nova Taylor
Company Secretary
(03) 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare and technology company which is focused on developing inhalation therapies. The Company currently markets the Medihale inhalation device and is working on developing a range of inhaled therapeutic medicinal formulations for registration domestically and internationally.